Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Glioma × niraparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 15 Breast Neoplasms 6 Neoplasms 5 Fallopian Tube Neoplasms 4 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Triple Negative Breast Neoplasms 2 Prostatic Neoplasms, Castration-Resistant 2 Neoplasm Metastasis 2 Esophageal Neoplasms 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Urologic Neoplasms 1 Stomach Neoplasms 1 Prostate Adenocarcinoma 1 Pancreatic Adenocarcinoma 1 Osteosarcoma 1 Oligodendroglioma 1 Neuroblastoma 1 Metastatic Castration-sensitive Prostate Cancer 1 Mesothelioma 1 Melanoma 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Glioma 1 Glioblastoma 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Cholangiocarcinoma 1

Interventions

Temozolomide 42 Bevacizumab 38 Radiotherapy 16 Magnetic Resonance Spectroscopy 12 Irinotecan 11 Nivolumab 7 Everolimus 6 Radiation 5 Carboplatin 5 poly ICLC 4 pembrolizumab 4 X-Rays 4 Phantoms, Imaging 4 Erlotinib Hydrochloride 4 Carmustine 4 ribociclib 3 fluorodopa F 18 3 Vorinostat 3 Specimen Handling 3 Radiotherapy, Intensity-Modulated 3 Radiosurgery 3 Nuclear Medicine Department, Hospital 3 Modafinil 3 Lomustine 3 trametinib 2 selinexor 2 plerixafor 2 perampanel 2 palbociclib 2 lenvatinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05297864 2025-05-23

OU-SCC-PI-4G

University of Oklahoma

Phase 2 Terminated

15 enrolled 13 charts

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡